
|Articles|November 7, 2012
FDA approves agent for RA patients who do not respond to methotrexate
FDA has approved tofacitinib (Xeljanz, Pfizer) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
REM-Dominant Sleep Apnea Significantly More Prominent Following COVID-19
2
Expert Addresses Pharmacy’s Uncertainty Amid MFN Drug Pricing Policy
3
Scripted for Her: HRT Black Box Removal
4
Pharmacists Empower Patients to Improve Insulin Management
5























































































































